Why the study?
Although acetylsalicylic acid is the standard for preventing cardiovascular complications in coronary heart disease, a number of patients remain at risk for atherothrombosis.
Does acetylsalicylic acid alter thrombus formation activity assessed by integral hemostasis tests in patients with stable CAD compared to controls?
Does acetylsalicylic acid alter thrombus formation activity assessed by integral hemostasis tests in patients with stable CAD compared to controls?
Acetylsalicylic acid significantly reduces thrombus formation activity as measured by the T-TAS system in patients with stable CAD compared to controls.
T-TAS AUC10 reduction may reflect ASA effect in stable CAD; hypothesis-generating and requires prospective confirmation.
Despite the fact that acetylsalicylic acid (ASA) is the "gold" standard for the prevention of cardiovascular complications in patients with coronary heart disease (CAD), a number of patients still have risks of atherothrombosis. In the present study, the antithrombotic effect of ASA in patients with CAD was assessed in platelet-rich plasma (PRP) using integral tests of the hemostasis study: the T-TAS system (Total Thrombus-formation Analysis System) and the thrombin generation test (TGT). The study involved 34 patients with stable CAD (11 women, 23 men) and people (15 women, 18 men) in the control group. As a result of assessing the activity of thrombus formation using the T-TAS system, a significant decrease in the area under the curve (AUC10) was found in the group with CAD patients compared with the control (135.6 [88.0-222.3] and 260.5 [217.3-301.9], respectively, p.
No takes yet. Share an insight, caveat, or question.
Melnichnikova et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: